Folio · SPXSet Report · Digest
v0.7.0 STABLE · 2026-11-11 · r4

2026-W46 · Nov 9–Nov 15 · Company · Profile · published

Index >>> Company >>> Profile

Illumina, Inc. (ILMN) — XLV Health Care · S&P 500 Profile |因美納公司介紹

health-careS&P500xlv
SPXSet Studio
IN-HOUSE RESEARCH · 站內獨立研究

Illumina, Inc. (ILMN) — Business, History & S&P 500 Profile | 因美納公司介紹

Illumina, Inc. company profile · business segments · history · financial snapshot · S&P 500 rank #289 · 因美納公司業務歷史財務與標普500地位

中文版 ↓

PROFILE
Market data as of Nov 3, 2026
Financials: FY2025
MARKET CAP
$36.24B
Nov 3, 2026
S&P 500 WEIGHT
0.05%
Rank #289 · Nov 3, 2026
SECTOR RANK
#36
Health Care · Nov 3, 2026
S&P 500 RANK
#289
0.05% · Nov 3, 2026

SNAPSHOT

TickerILMN
CompanyIllumina, Inc.
GICS sector / industryHealth Care (XLV) / Life Sciences Tools & Services
S&P 500 rank (by weight)#289 · 0.05% (Nov 3, 2026)
Sector rank#36 of 60 in Health Care (Nov 3, 2026)
HeadquartersSan Diego, California
Founded1998
CEOJacob Thaysen (Chief Executive Officer)
Employees8,600 full-time (2025)
Market cap$36.24B (Nov 3, 2026)
Share price$238.94 (Nov 3, 2026)
SEC filingsEDGAR — CIK 0001110803

WHAT IT DOES

Illumina, Inc. is the world's leading maker of DNA sequencing systems, headquartered in San Diego, California. Its sequencers, consumables and analysis software are the default platform for genomic research and, increasingly, for clinical testing in oncology, reproductive health and rare disease.

Its one-line model: sell sequencing instruments into laboratories, then earn recurring high-margin revenue from the proprietary consumables each instrument consumes — in fiscal 2025 consumables were $3.23B of $4.34B total revenue (about 74%), against $482M of instruments and $634M of service and other revenue.

Illumina reports a single segment, Core Illumina, after spinning off its GRAIL cancer-detection unit in June 2024. Fiscal 2025 revenue was $4.34B, roughly flat against $4.37B a year earlier, and the company returned to profit — net income of $850M after a fiscal 2024 net loss of $1.22B that was driven largely by GRAIL-related charges.

BUSINESS SEGMENTS

ConsumablesSequencing consumables — flow cells, reagents and kits consumed by the installed base — fiscal 2025 revenue of $3,227M, about 74% of the total and the recurring core of the model.
InstrumentsSequencing systems including the NovaSeq X series and mid-throughput instruments — fiscal 2025 revenue of $482M.
Service and otherInstrument service contracts, training and other services — fiscal 2025 revenue of $634M.

HISTORY

YearMilestone
1998Illumina is founded in San Diego, California, built initially around bead-array technology.
2000Illumina lists on Nasdaq in its initial public offering.
2007Illumina acquires Solexa for about $600M, gaining sequencing-by-synthesis technology — the foundation of its modern sequencing business.
2014The HiSeq X Ten launches, marketed as the first $1,000-genome system.
2017The NovaSeq series launches, extending high-throughput sequencing; the NovaSeq X follows in 2022.
2021Illumina closes its roughly $8B acquisition of GRAIL in August 2021 despite U.S. and EU antitrust objections.
2023Jacob Thaysen becomes chief executive in September 2023.
2024After regulators order divestiture, Illumina spins off GRAIL to shareholders on June 24, 2024, retaining a minority stake.

COMPETITIVE POSITION

  • Installed-base economics: consumables were about 74% of fiscal 2025 revenue, tying results to utilisation of the global sequencer fleet rather than to instrument placements alone.
  • Scale and share: Illumina remains the largest sequencing platform by installed base and revenue, well ahead of Pacific Biosciences, Oxford Nanopore and newer entrants such as Ultima Genomics and Element Biosciences.
  • Clinical shift: growth is led by clinical sequencing (oncology, rare disease, reproductive health) as research demand softens with tighter academic funding.
  • Competition set: Thermo Fisher Scientific, Pacific Biosciences, Oxford Nanopore, Ultima Genomics, Element Biosciences and MGI/BGI outside the U.S.

FINANCIAL SNAPSHOT

Total revenue$4.34B (FY2025 revenue)
Operating income$807M (FY2025 operating income)
Net income$850M (FY2025 net income)
Diluted EPS$5.45 (FY2025 diluted EPS)
Source: Illumina fiscal 2025 Form 10-K (year ended December 28, 2025), figures via SEC EDGAR company data, corroborated by the Wikipedia company profile. Fiscal 2024 comparatives include GRAIL until its June 24, 2024 spin-off; fiscal 2024 net loss of $1,223M was driven largely by GRAIL-related charges.

KEY RISKS

  • China restrictions: China's commerce ministry placed Illumina on its unreliable entity list in February 2025 and its China business has been curtailed since, removing a historically important growth market.
  • Research funding: a large share of demand traces to government-funded research budgets, notably U.S. NIH funding, which faces political pressure.
  • Competition on price and throughput from Ultima Genomics, Element Biosciences, Pacific Biosciences and MGI/BGI, especially outside the U.S.
  • Instrument placement cycles: high-throughput placements depend on laboratory capital budgets; a placement slowdown compounds through consumables with a lag.
  • Tariffs and trade measures raised costs in 2025–2026; the company's 2026 reporting has separately discussed tariff refunds and China exclusions.

WHY IT MATTERS FOR THE S&P 500

Illumina is a small-weight health-care constituent: rank #289 by weight at 0.05% as of Nov 3, 2026, and #36 in Health Care. As the index's dominant genomics-sequencing platform, it is the cleanest listed read on global sequencing adoption in research and clinical settings.

SOURCES & METHODOLOGY

Financials, segments, headquartersIllumina, Inc. fiscal 2025 Form 10-K data via SEC EDGAR (see Financial Snapshot note); headquarters, CEO and employees via the Form 10-K and Wikipedia company profile
Index weight & ranksSlickcharts S&P 500 weights, fetched Nov 3, 2026; sector membership per Wikipedia List of S&P 500 companies (GICS)
Market cap$36.24B (Slickcharts, Nov 3, 2026)
LogoSPXSet logo library, compiled from company official websites, filings, or Wikipedia; as company logos are dynamic corporate information, no 100% guarantee is made for the graphics.
ChartSPXSet chart library, monthly bars, compiled from Yahoo public information.

Price Chart — 10-Year Monthly Candles

ILMN

Source: Yahoo Finance monthly bars, split-adjusted · Data as of Sep 30, 2026 (last closed month) · SPXSet.com

FINANCIALS

繁體中文版

公司快照

股票代號ILMN
公司Illumina, Inc.(因美納)
GICS 板塊/行業醫療保健(XLV)/生命科學工具與服務
標普500排名(按權重)#289 · 0.05%(Nov 3, 2026)
板塊內排名醫療保健 #36(共 60 家)(Nov 3, 2026)
總部美國加利福尼亞州聖迭戈
成立1998年
執行長Jacob Thaysen(執行長)
員工8,600 名全職(2025年)
市值$36.24B(Nov 3, 2026)
股價$238.94(Nov 3, 2026)
SEC 申報EDGAR — CIK 0001110803

業務概覽

因美納是全球領先的 DNA 測序系統製造商,總部位於美國加利福尼亞州聖迭戈。其測序儀、耗材與分析軟件是基因組學研究的預設平台,並日益用於腫瘤、生殖健康與罕見病的臨床檢測。

其一句話商業模式是:向實驗室出售測序儀,再從每台儀器消耗的專有耗材賺取經常性高毛利收入——2025 財年耗材收入 32.27 億美元,佔總收入 43.43 億美元約 74%,儀器收入 4.82 億美元,服務及其他收入 6.34 億美元。

因美納於 2024 年 6 月分拆癌症檢測部門 GRAIL 後,只設一個報告板塊(Core Illumina)。2025 財年收入 43.43 億美元,與上年 43.72 億美元大致持平,公司重回盈利——淨利潤 8.50 億美元,而 2024 財年淨虧損 12.23 億美元,主要源於 GRAIL 相關費用。

業務板塊

耗材測序耗材——裝機基礎消耗的流動槽、試劑與套裝——2025 財年收入 32.27 億美元,約佔總收入 74%,是商業模式的經常性核心。
儀器測序系統,包括 NovaSeq X 系列及中通量儀器——2025 財年收入 4.82 億美元。
服務及其他儀器服務合約、培訓及其他服務——2025 財年收入 6.34 億美元。

歷史

年份里程碑
1998因美納於加利福尼亞州聖迭戈成立,最初以微珠陣列技術為基礎。
2000因美納在納斯達克首次公開招股上市。
2007因美納以約 6 億美元收購 Solexa,取得邊合成邊測序技術——其現代測序業務的基礎。
2014HiSeq X Ten 推出,宣傳為首個「1,000 美元基因組」系統。
2017NovaSeq 系列推出,擴展高通量測序;NovaSeq X 於 2022 年跟隨推出。
2021因美納於 2021 年 8 月完成約 80 億美元的 GRAIL 收購,儘管美國與歐盟反壟斷機構反對。
2023Jacob Thaysen 於 2023 年 9 月出任執行長。
2024監管機構命令剝離後,因美納於 2024 年 6 月 24 日將 GRAIL 分拆予股東,保留少數股權。

競爭地位

  • 裝機基礎經濟學:耗材約佔 2025 財年收入 74%,業績與全球測序儀機隊的使用率掛鈎,而非僅取決於儀器出貨。
  • 規模與份額:因美納仍是按裝機量與收入計最大的測序平台,明顯領先 Pacific Biosciences、Oxford Nanopore 及 Ultima Genomics、Element Biosciences 等新進入者。
  • 臨床轉向:增長由臨床測序(腫瘤、罕見病、生殖健康)帶動,研究需求則因學術經費收緊而放緩。
  • 競爭對手:Thermo Fisher Scientific、Pacific Biosciences、Oxford Nanopore、Ultima Genomics、Element Biosciences 及美國以外的 MGI/華大。

財務快照

總收入$4.34B(FY2025 收入)
營業利潤$807M(FY2025 營業利潤)
淨利潤$850M(FY2025 淨利潤)
稀釋 EPS$5.45(FY2025 稀釋 EPS)
來源:因美納 2025 財年 Form 10-K(截至 2025 年 12 月 28 日),數字經 SEC EDGAR 公司數據,並經維基百科公司資料核對。2024 財年比較數字包括 GRAIL(直至 2024 年 6 月 24 日分拆);2024 財年淨虧損 12.23 億美元主要源於 GRAIL 相關費用。

主要風險

  • 中國限制:中國商務部於 2025 年 2 月將因美納列入不可靠實體清單,其中國業務自此受限,失去一個歷來重要的增長市場。
  • 研究經費:相當部分需求源於政府資助的研究預算,尤其是面臨政治壓力的美國 NIH 經費。
  • 價格與通量競爭:Ultima Genomics、Element Biosciences、Pacific Biosciences 及 MGI/華大,尤其在美國以外市場。
  • 儀器出貨週期:高通量儀器出貨取決於實驗室資本預算;出貨放緩會滯後地傳導至耗材。
  • 關稅與貿易措施在 2025–2026 年推高成本;公司 2026 年披露曾另行討論關稅退款與中國排除因素。

對標普500的重要性

因美納是權重較小的醫療保健成分股:按權重排名 #289,權重 0.05%(以 2026 年 11 月 3 日為準),醫療保健板塊內排名 #36。作為指數中主導的基因組測序平台,它是觀察全球研究與臨床測序普及的最清晰上市指標。

來源與方法

財務、板塊、總部因美納 2025 財年 Form 10-K 數據,經 SEC EDGAR(見財務快照附註);總部、執行長與員工經 Form 10-K 及維基百科公司資料
指數權重與排名Slickcharts 標普 500 權重,Nov 3, 2026 抓取;板塊歸屬按維基百科標普 500 成分股名單(GICS)
市值$36.24B(Slickcharts,Nov 3, 2026)
LogoSPXSet logo 庫,整理自企業官方網站、文件或維基百科;由於是企業自身動態資訊,不對圖形做百分百保證。
股價圖SPXSet 圖表庫月線,整理自 Yahoo 公開資訊。

10年股價K線圖(月K)

ILMN

來源:Yahoo Finance 月線(經拆股調整)· 數據截至 2026 年 9 月 30 日(最後已收月份)· SPXSet.com

財報

SPXSet Studio

SPXSet in-house research — market structure, options and volatility. Not investment advice.
SPXSet 站內獨立研究,聚焦 SPX 市場結構、期權與波動率;內容不構成投資建議。

SPXSet · Company Library · ILMN
Data as of Nov 3, 2026 · Financials FY2025 (10-K) · Market data Nov 2026
Previous · GE HealthCare Technologies Inc. (GEHC) — XLV Health Care · S&P 500 Profile |GE 醫療公司介紹Next · Take-Two Interactive Software, Inc. (TTWO) — XLC Communication Services · S&P 500 Profile |Take-Two 互動娛樂公司介紹

Entered 2026-11-03 10:33 · updated 2026-11-14 23:35 · rev 7